ASH: With Yescar­ta lead­ing in ear­li­er-line lym­phoma, Bris­tol My­ers keeps the heat on with full da­ta for Breyanzi

Kick­ing off this week­end’s #ASH21, Gilead’s Kite and Bris­tol My­ers Squibb have re­leased com­pet­ing da­ta for their cur­rent-gen CAR-T drugs in sec­ond-line B cell lym­phoma pa­tients. It’s a heat­ed con­test to move these drugs in­to ear­li­er lines of ther­a­py, and Bris­tol My­ers thinks these fuller da­ta will keep the pres­sure on.

Bris­tol My­ers’ Breyanzi (liso­cab­ta­gene mar­aleu­cel) cut the risk of dis­ease pro­gres­sion, death and oth­er events by 65% over stan­dard of care in sec­ond-line re­lapsed or re­frac­to­ry LB­CL pa­tients, ac­cord­ing to da­ta from the Phase III TRANS­FORM study pre­sent­ed Sat­ur­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN